Sulfatides for the treatment of autoimmune disorders

Bibliography

• KRONENBERG M: Toward an understanding of NKT cell biology: progress and paradoxes. Ann. Rev. Immunol. (2005) 23:877-900.
   PubMed Web of Science ®Google Scholar
• BENDELAC A, SAVAGE PB, TEYTON L: The biology of NKT cells. Ann. Rev. Immunol. (2007) 25:297-336.
   PubMed Web of Science ®Google Scholar
• CERUNDOLO V, SALIO M: Harnessing NKT cells for therapeutic applications. Curr. Top. Microbiol. Immunol. (2007) 314:325-340.
   PubMedGoogle Scholar
• MIYAKE S, YAMAMURA T: NKT cells and autoimmune diseases: unraveling the complexity. Curr. Top. Microbiol. Immunol. (2007) 314:251-267.
   PubMedGoogle Scholar
• BRIGL M, BRENNER MB: CD1: antigen presentation and T cell function. Ann. Rev. Immunol. (2004) 22:817-890.
   PubMed Web of Science ®Google Scholar
• GODFREY DI, KRONENBERG M: Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. (2004) 114:1379-1388.
   PubMed Web of Science ®Google Scholar
• VAN KAER L: α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. (2005) 5:31-42.
   PubMedGoogle Scholar
• VAN KAER L: Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol. Res. (2004) 30:139-153.
   PubMedGoogle Scholar
• MIYAMOTO K, MIYAKE S, YAMAMURA T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 413:531-534.
   PubMed Web of Science ®Google Scholar
• CHARBONNIER LM, VAN DUIVENVOORDE LM, APPARAILLY F et al.: Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells. J. Immunol. (2006) 177:3806-3813.
   PubMed Web of Science ®Google Scholar
• MIZUNO M, MASUMURA M, TOMI C et al.: Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J. Autoimmun. (2004) 23:293-300.
   PubMed Web of Science ®Google Scholar
• OSMAN YKT, NAITO T, TAKEDA K, VAN KAER L, OKUMURA K, ABO T: Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. (2000) 30:1919-1928.
   PubMed Web of Science ®Google Scholar
• BIBURGER M, TIEGS G: α-Galactosylceramide-induced liver injury in mice is mediated by TNF-α but independent of Kupffer cells. J. Immunol. (2005) 175:1540-1550.
   PubMed Web of Science ®Google Scholar
• ZHOU D: The immunological function of iGb3. Curr. Protein Pept. Sci. (2006) 7:325-333.
   PubMedGoogle Scholar
• GODFREY DI, MCCONVILLE MJ, PELLICCI DG: Chewing the fat on natural killer T cell development. J. Exp. Med. (2006) 203:2229-2232.
   PubMedGoogle Scholar
• BEHAR SM, PORCELLI SA: CD1-restricted T cells in host defense to infectious diseases. Curr. Top. Microbiol. Immunol. (2007) 314:215-250.
   PubMed Web of Science ®Google Scholar
• LALAZAR G, PRESTON S, ZIGMOND E, BEN YAACOV A, ILAN Y: Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. (2006) 6:1249-1253.
   PubMed Web of Science ®Google Scholar
• TSUJI M: Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol. Life Sci. (2006) 63:1889-1898.
   PubMedGoogle Scholar
• MARGALIT M, GHAZALA SA, ALPER R et al.: Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 289:G917-G925.
   PubMedGoogle Scholar
• STANIC AK, DE SILVA AD, PARK JJ et al.: Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA (2003) 100:1849-1854.
   PubMedGoogle Scholar
• HAUBEN E, RONCAROLO MG, NEVO U, SCHWARTZ M: Beneficial autoimmunity in Type 1 diabetes mellitus. Trends Immunol. (2005) 26:248-253.
   PubMed Web of Science ®Google Scholar
• BRUTKIEWICZ RR: CD1d ligands: the good, the bad, and the ugly. J. Immunol. (2006) 177:769-775.
   PubMed Web of Science ®Google Scholar
• MARGALIT M, SHALEV Z, PAPPO O et al.: Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J. Pharmacol. Exp. Ther. (2006) 319:105-110.
   PubMedGoogle Scholar
• ZIGMOND E, PRESTON S, PAPPO O et al.: β-Glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut (2007) 56:82-89.
   PubMed Web of Science ®Google Scholar
• ZIGMOND EPO, ZANGEN S, LEVY SKLAIR M et al.: Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: a Phase I/II clinical study. Hepatology (2006) 44:A180.
   Google Scholar
• JAHNG AW, MARICIC I, PEDERSEN B et al.: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. (2001) 194:1789-1799.
   PubMed Web of Science ®Google Scholar
• ZAJONC DM, MARICIC I, WU D et al.: Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. (2005) 202:1517-1526.
   PubMed Web of Science ®Google Scholar
• SAVAGE PB, TEYTON L, BENDELAC A: Glycolipids for natural killer T cells. Chem. Soc. Rev. (2006) 35:771-779.
   PubMedGoogle Scholar
• SINGH AK, WILSON MT, HONG S et al.: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. (2001) 194:1801-1811.
   PubMed Web of Science ®Google Scholar
• JAHNG A, MARICIC I, AGUILERA C, CARDELL S, HALDER RC, KUMAR V: Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. (2004) 199:947-957.
   PubMed Web of Science ®Google Scholar
• HALDER RC, JAHNG A, MARICIC I, KUMAR V: Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem. Res. (2007) 32:257-262.
   PubMedGoogle Scholar
• NOVAK J, GRISERI T, BEAUDOIN L, LEHUEN A: Regulation of Type 1 diabetes by NKT cells. Int. Rev. Immunol. (2007) 26:49-72.
   PubMed Web of Science ®Google Scholar
• ILAN Y, OHANA M, PAPPO O et al.: Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation (2007) 83:458-467.
   Google Scholar
• MEYER EH, GOYA S, AKBARI O et al.: Glycolipid activation of invariant T cell receptor + NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc. Natl. Acad. Sci. USA (2006) 103:2782-2787.
   PubMed Web of Science ®Google Scholar